

Regulation of signal transduction pathways in development by glycosylation

Robert S Haltiwanger

Recent studies from several laboratories have provided evidence that cell surface complex carbohydrates play key roles in the regulation of developmentally relevant signal transduction events. The demonstration that Fringe, a known modifier of Notch function, is a fucose-specific *N*-acetylglucosaminyltransferase provided strong evidence that the Notch signaling pathway could be regulated by alterations of *O*-fucose structures. More recently, the demonstration that *O*-fucose modification of Cripto is essential for Nodal-dependent signaling provides further evidence of a role for glycosylation in signal transduction. These and other examples provide a new paradigm for the regulation of signal transduction events by glycosylation.

Address

Department of Biochemistry and Cell Biology, Institute for Cell and Developmental Biology, State University of New York at Stony Brook, Stony Brook, New York 11794-5215, USA

Current Opinion in Structural Biology 2002, 12:593–598

0959-440X/02/\$ – see front matter

© 2002 Elsevier Science Ltd. All rights reserved.

Abbreviations

CFC	Cripto, FRL-1, Cryptic
CSL	CBF1, Suppressor of hairless, Lag-1
EGF	epidermal growth factor
GlcNAc	<i>N</i> -acetylglucosamine
GPI	glycosyl phosphatidyl inositol
<i>O</i> -FucT-1	GDP-fucose: protein <i>O</i> -fucosyltransferase 1
TGFβ	transforming growth factor β
uPA	urinary-type plasminogen activator

Introduction

The discovery of the complexity and diversity of complex carbohydrates on the cell surface led researchers over 30 years ago to hypothesize that glycoconjugates play roles in communication between cells and in the transfer of information from the outside of the cell to the inside [1]. As this type of communication is essential for numerous stages of development, specific carbohydrate modifications were proposed to play roles in particular biological events at the cell surface. Over the years, numerous observations have supported this concept. Early on, many of the stage-specific embryonic antigens (e.g. SSEA-1, SSEA-3, SSEA-4, HNK-1) were demonstrated to be specific carbohydrate structures [2]. For instance, SSEA-1 is the Lewis x oligosaccharide, SSEA-3 and SSEA-4 are glycolipids of the globo series, and HNK-1 is a sulfated glycan. The expression of unique glycan structures at specific stages implied a particular function for that structure. The demonstration that the presence or absence of polysialic acid alters homotypic interactions of the neural cell adhesion molecule (NCAM) added further support [2]. More recently,


the demonstration of embryonic lethality resulting from the genetic ablation of several glycosyltransferases has revealed that particular carbohydrate structures are essential for development to proceed past certain stages [3]. Nonetheless, with the exception of NCAM, identifying examples of particular carbohydrate structures on specific proteins mediating such effects was, for many years, elusive. Recent work has begun to identify some of these molecules. The first examples came with the demonstration that cell surface heparan sulfate proteoglycans play an essential role in Wnt, hedgehog, FGF (fibroblast growth factor) and TGFβ (transforming growth factor β) superfamily pathways. More recently, *O*-fucose modifications of epidermal growth factor (EGF)-like repeats have been shown to modulate Notch, TGFβ family (Nodal) and urinary-type plasminogen activator (uPA) signal transduction. Several excellent recent reviews have been written concerning the role of heparan sulfate proteoglycans in development [4–6] and thus will not be considered further here. This review will focus on the recent studies of the *O*-fucose modifications of EGF repeats of Notch, Cripto and uPA.

Involvement of *O*-fucose modifications of EGF repeats in signal transduction

O-linked carbohydrate modifications of EGF repeats

Fucose *O*-linked to serine or threonine was first observed over 25 years ago as amino acid fucosides isolated from human urine [7]. The first protein reported to bear *O*-fucose was uPA [8], quickly followed by tissue-type plasminogen activator and several clotting factors (factors VI, IX and XII) [9]. Comparison of the sequences surrounding the sites of *O*-fucose modification on these proteins showed the fucose to be localized to a putative consensus sequence within EGF repeats. EGF repeats are small (approximately 40 amino acid) protein motifs originally observed in epidermal growth factor. They are defined by the presence of six conserved cysteine residues that form three disulfide bonds (Figure 1; [10]). EGF repeats occur in dozens of cell surface and secreted proteins, and are known to play roles in protein–protein interactions. The *O*-fucose modification occurs between the second and third conserved cysteines of the putative consensus sequence C²XXGGS/TC³ [9]. Proteins predicted to be modified with *O*-fucose based on the presence of this consensus sequence have been demonstrated to bear the modification [11•–14•], indicating that it can be used to make accurate predictions about whether a protein will bear *O*-fucose (Table 1). Recent work has suggested that the originally proposed consensus site is too narrow and that *O*-fucose modifications occur more broadly than predicted [14•]. As a result, a broader consensus site, C²X_{3–5}S/TC³, has recently been proposed.

Figure 1



EGF repeat modified with the *O*-fucose tetrasaccharide. A representation of an EGF repeat (based on EGF1 from factor VII [18]) modified with the *O*-fucose tetrasaccharide is shown. The conserved cysteines of the EGF repeat are in yellow and are numbered, and the disulfide bonds between them (C¹–C³, C²–C⁴ and C⁵–C⁶) are shown. The serine (shown) or threonine modified with *O*-fucose is in blue, and the other amino acids between C² and C³ are shown as X. The number of Xs can vary between 3 and 5 [14•]. The enzymes responsible for the addition of each saccharide are indicated: *O*-FucT-1 [15–17], Fringe [30••,37••], β 4GalT1 [39•] and either α 2,3SiaT (shown) or α 2,6SiaT [11•,30••]. Adapted from [30••].

The enzyme responsible for the addition of *O*-fucose to EGF repeats, GDP-fucose: protein *O*-fucosyltransferase 1 (*O*-FucT-1), has been identified and cloned [15,16]. *O*-FucT-1 appears to be a type II membrane glycoprotein like most glycosyltransferases involved in the addition of sugars to proteins. It will not fucosylate synthetic peptides containing the consensus sequence for *O*-fucose addition, but requires a properly folded EGF repeat containing the consensus sequence (Figure 1; [15,17]). Homologs have been identified in species from *Caenorhabditis elegans* to humans, an expression pattern that is consistent with the distribution of proteins containing EGF repeats.

The structure of the EGF repeat from factor VII with and without the *O*-fucose has been determined using NMR [18]. Although the *O*-fucose presents a significant epitope on one face of the EGF repeat, no major conformational change in the polypeptide structure was observed. Thus, alterations in function due to changes in glycosylation are more likely to result from direct interactions with the carbohydrates or from steric blocking of a protein–protein interaction by the carbohydrate.

Early work on the function of *O*-fucose modifications indicated a role in modulating receptor–ligand interactions. Binding of uPA to the uPA receptor results in the activation of several signaling cascades within cells [19]. The EGF repeat of uPA is necessary and sufficient to activate the uPA receptor. Interestingly, removal of the *O*-fucose from the EGF repeat (either chemically or by synthesis in

Table 1

***O*-fucose-modified proteins*.**

Proteins known to be modified with *O*-fucose.

Blood clotting/dissolution

Urokinase (uPA) [8]
Tissue-type plasminogen activator (tPA) [46]
Desmodus (bat) salivary plasminogen activator [47]
Factor VII [48]
Factor IX [49]
Factor XII [50]

Notch signaling

Notch [11',30'']
Delta [14']
Serrate [14']
Jagged [14']

TGF β signaling

Cripto [12',13']

Other

Fetal antigen-1/Delta-like protein (FA1/DLK) [51]
Proteins predicted to be modified with *O*-fucose based on the presence of the consensus sequence (C-X-X-G-G-S/T-C).

Slit
Crumbs
Cryptic
LDL receptor-related protein (LRP)
Acrogranin/epithelin
Brevican (PCCB)
Neurocan (PGCN)
Agrin
Hepatocyte growth factor activator
One-eyed pinhead
FRL-1
Versican (PGCV)
Multimerin
Fibrillin
Fibropellin
Perlecan (PGBM)

*Proteins that have been identified to contain *O*-fucose are listed along with proteins that contain the consensus sequence for *O*-fucose addition and may be modified. Proteins containing a consensus sequence within an EGF module were found by searching the sequence databases Swiss-Prot and PIR (Protein Information Resource) at the MOTIF web site (www.motif.genome.ad.jp) using the query pattern C-x-x-G-G-[ST]-C. Note that searches with the broader consensus site (C²X₃₋₅S/TC³) are not informative due to the large number of proteins identified. Adapted from [52].


bacteria in which fucosylation does not occur) abrogates uPA receptor activation, although it has no effect on the binding of the EGF repeat to the receptor [20]. The mechanism by which the *O*-fucose activates the receptor is unknown, but these results demonstrate that the presence or absence of a simple sugar on an EGF repeat can regulate a signal transduction event.

Fringe is an *O*-fucose: β 1,3-*N*-acetylglucosaminyl-transferase that modulates Notch signaling

Another example of how a signaling event can be regulated by alterations of carbohydrate structures on EGF repeats has been revealed in the Notch pathway. Notch is a large cell surface receptor protein that plays an essential role in numerous developmental events (for recent reviews on

Figure 2

Fringe modulates ligand-mediated activation of Notch (for a recent review on Notch activation, see [22]). Notch activation proceeds through five steps. (i) Notch in the signal-receiving cell becomes activated upon binding to Notch ligands (Delta and Serrate/Jagged) expressed on the cell surface of the sending cell. (ii) Ligand binding stimulates proteolytic cleavage of the extracellular domain of Notch at site 2 (S2) catalyzed by TACE. (iii) Release of the extracellular domain of Notch stimulates intramembranous cleavage at site 3 (S3) catalyzed by γ -secretase. (iv) γ -Secretase cleavage releases the intracellular domain from the membrane as a soluble protein in the cytoplasm. (v) The Notch intracellular domain translocates to the nucleus, where it interacts with the CSL family of transcriptional regulators to activate transcription. (vi) Ligand expressed in the same cell as Notch can inhibit activation through cell autonomous inhibition [53,54]. Fringe (Fng) modifies *O*-fucose residues on both Notch [30••,37••] and Notch ligands [14•], resulting in potentiation of signaling from Delta (Fng+) or inhibition of signaling from Serrate/Jagged (Fng-). *O*-fucose is represented by a triangle; β 1,3-GlcNAc added by Fringe is a square; β 1,4-galactose is a circle; α 2,3/6-sialic acid is a diamond. The brackets indicate the carbohydrates that are added in response to Fringe action. The addition of the sialic acid is not necessary for Fringe to exert its effects on Jagged1-dependent Notch activation and, thus, is presented as +/- [39•]. Adapted from [30••].




Current Opinion in Structural Biology

Notch, see [21,22]). A variety of human diseases are caused by defects in Notch signaling, including T-cell leukemias, CADASIL, spondylocostal dysostosis and Alagille syndrome [23–25]. The extracellular domain of Notch is composed largely of tandem EGF repeats (36 in *Drosophila* Notch and mammalian Notch1 and Notch2), several of which contain consensus sites for *O*-fucose modification [11•]. The recent finding of a broader consensus site for *O*-fucose modification has greatly expanded the number of potential sites on Notch [14•]. Notch activation is initiated by ligand binding. Interestingly, Notch ligands (Delta and Serrate/Jagged) are also transmembrane proteins. Thus, Notch activation requires the expression of a ligand on an adjacent cell (Figure 2). Binding of ligand initiates a proteolytic event catalyzed by TACE, a member of the ADAMS family of metalloproteases, whereby the extracellular domain of Notch is released from the membrane. This is followed by another proteolytic event, just inside the membrane, catalyzed by γ -secretase. After the cytoplasmic domain of Notch is released from the membrane, it translocates to the nucleus, where it binds to members of the CSL (CBF1, Suppressor of hairless, Lag-1) family of transcriptional regulators, resulting in the activation of several downstream genes.

Notch activation can be regulated at several points within the signaling pathway. The Fringe protein was identified in *Drosophila* as a modulator of Notch activation, capable of potentiating signaling from Delta while inhibiting signaling from Serrate/Jagged (reviewed in [26,27]; Figure 2). Mutations in *fringe* result in defects in the proper development of several tissues in *Drosophila*, including wings, eyes and legs. Three Fringe homologs exist in mammals (Lunatic fringe, Manic fringe and Radical fringe) that are all capable of complementing *fringe* mutants in *Drosophila* [28,29]. Cell-based signaling assays have confirmed that Lunatic and Manic fringe can inhibit Jagged1-dependent Notch activation and stimulate Delta1-dependent activation [30••,31•,32•]. Genetic ablation of *Lunatic fringe* in mice results in fusion of somites, skeletal defects and perinatal death [33,34], although no obvious phenotype was observed in mice lacking *Radical fringe* [35,36]. No data are yet available on phenotypes of *Manic fringe* knockouts. Thus, Fringe carries out a variety of essential developmental functions by modulating Notch activity.

Fringe modulates Notch activity by altering the *O*-fucose carbohydrate structures on EGF repeats. Fringe is an

Figure 3



Modification of Cripto with *O*-fucose is essential for Nodal-dependent signaling (for a review of the Nodal signaling pathway, see [41–43]). Nodal signaling proceeds through four steps. (i) The interaction of Nodal with Cripto is dependent on the presence of *O*-fucose on Cripto [12*,13*]. Cripto can be either linked to the cell surface through a GPI anchor (as shown) or soluble [13*]. (ii) The Cripto–Nodal complex activates the type I and type II activin-like receptors. (iii) The activated receptors phosphorylate cytoplasmic Smad2 (or Smad3). (iv) Phosphorylation of the Smad proteins results in nuclear accumulation, where they interact with the FAST (FoxH1) family of transcriptional regulators and activate transcription. *O*-fucose is represented by a triangle, the EGF repeat by a red circle and the CFC domain by a hexagon. Adapted from [41].

O-fucose: β 1,3-*N*-acetylglucosaminyltransferase, responsible for the addition of β -linked *N*-acetylglucosamine (GlcNAc) residues to the 3'-hydroxyl groups of *O*-fucose on EGF repeats (Figure 1; [30**,37**,38**]). The *N*-acetylglucosaminyltransferase activity is essential for Fringe to be able to mediate its effects on Notch signaling. The addition of GlcNAc to *O*-fucose by Fringe is believed to be a Golgi event [37**] and (in mammals) is followed by the addition of a β 1,4-linked galactose and an α 2,3-linked sialic acid (Figure 1; [30**]). Recent work has shown that Fringe-mediated inhibition of Jagged1-dependent Notch activation requires the addition of the β 1,4-galactose but not the sialic acid [39*]. The mechanism by which the altered carbohydrate structure changes the ability of Notch to respond to its ligands is an area of active research. Several models have been proposed (see [40*] for details), including direct modulation of ligand binding and alteration of the cell autonomous inhibition of Notch by ligands (Figure 2). The recent demonstration that Fringe can

modify *O*-fucose residues on the ligands as well as on Notch [14*] has raised the interesting possibility that Fringe could function through the modification of either or both the ligand and receptor. Studies are currently underway to examine these possibilities.

***O*-fucose modification of Cripto is essential for Nodal signaling**

Nodal is a member of the TGF β superfamily and plays an important role in establishing polarity in the vertebrate embryo (for recent reviews, see [41,42]). *Nodal* mutants in mice and zebrafish (*Nodal* homologs *cyclops* and *squint*) show severe defects in mesoderm formation and left/right axis determination. Nodal is believed to activate type I and type II activin-like receptors, leading to phosphorylation-induced accumulation of Smads in the nucleus (Figure 3). Once in the nucleus, the Smads associate with nuclear transcription factors of the FAST (FoxH1) family, resulting in the altered transcription of several downstream genes. Nodal signaling is regulated at several levels and recent work has identified the EGF-CFC family of proteins (including mammalian Cripto and Cryptic, zebrafish one-eyed pinhead and *Xenopus* FRL-1) as essential cofactors for the activation of the activin-like receptors by Nodal (for a recent review, see [43]). The EGF-CFC proteins are small, GPI (glycosyl phosphatidyl inositol)-anchored cell surface proteins that contain a truncated EGF repeat (lacking amino acids between the first and second conserved cysteines) and another cysteine-rich domain termed CFC (for Cripto, FRL-1, Cryptic). The EGF repeat in each of the EGF-CFC family members contains an *O*-fucose consensus site and recent work has demonstrated that the site is modified with *O*-fucose in both human Cripto [12*] and mouse Cripto [13*]. Interestingly, mutation of the modified threonine to alanine prevents *O*-fucosylation and inhibits Cripto function in both cell-based signaling assays and *Xenopus* oocytes [12*,13*]. Thus, Nodal signaling is dependent on the presence of fucosylated EGF-CFC proteins. Recent work in the Shen [13*] laboratory has demonstrated that Cripto can activate Nodal signaling either bound to the cell surface or as a soluble factor, and that physical association with Nodal appears to be dependent on the presence of the fucose. These results raise the interesting possibility that *O*-fucosylation could represent an additional level of regulation of Nodal signaling.

Conclusions

The past decade has seen increasing numbers of examples of cell surface carbohydrates that play roles in signal transduction events. As hypothesized decades ago, the complexity of carbohydrates found on the cell surface argues for an informational role. Numerous developmentally relevant signaling pathways are affected by proteoglycans and the recent demonstration of the importance of *O*-fucose modifications in Notch and Cripto/Nodal signaling suggests that a new era of uncovering the involvement of glycans in signaling is beginning. Several other proteins involved in a variety of developmental and/or signaling

events are predicted to be modified with *O*-fucose (see Table 1). In addition, EGF repeats are also modified with *O*-glucose at consensus sites between the first and second conserved cysteines [9]. Many of the predicted *O*-glucose sites on the Notch receptor are evolutionarily conserved, suggesting these modifications will also play an important role in Notch signaling. Another form of *O*-fucose has recently been mapped to a consensus site on thrombospondin type 1 repeats [44]. Interestingly, the *O*-fucose site on thrombospondin type 1 repeats sits in the midst of a known heparan-sulfate-binding domain, suggesting this modification may modulate interactions at this site [45]. These and other examples suggest we are just scratching the surface of the role of glycosylation in the regulation of signal transduction.

Update

Recent work has shown that *Brainiac* is also a β 1,3-*N*-acetylglucosaminyltransferase, apparently modifying β -linked mannose or galactose on glycosphingolipids [55]. *Brainiac* exhibits sequence similarities with both *Drosophila* and mammalian Fringes, and *Brainiac* mutants show some resemblance to Notch mutants, indicating that *Brainiac* also may have an effect on the Notch pathway. The relationship between alterations in glycosphingolipid structure and Notch is not yet clear.

Acknowledgements

The author would like to thank Kenneth Irvine, Michael Shen, Li Shao, Kelvin Luther, Yi Luo, Raajit Rampal and Malgorzata Kokoszka for helpful comments. Original research was supported by National Institutes of Health grant GM61126.

References and recommended reading

Papers of particular interest, published within the annual period of review, have been highlighted as:

- of special interest
- of outstanding interest

1. Roseman S: **Reflections on glycobiology.** *J Biol Chem* 2001, **276**:41527-41542.
2. Marth JD: **Glycosylation changes in ontogeny and cell activation.** In *Essentials of Glycobiology*. Edited by Varki A, Cummings R, Esko J, Freeze H, Hart G, Marth J. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 1999:515-536.
3. Marth JD: **Determining glycan function using genetically modified mice.** In *Essentials of Glycobiology*. Edited by Varki A, Cummings R, Esko J, Freeze H, Hart G, Marth J. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 1999:499-514.
4. Perrimon N, Berfield M: **Specificities of heparan sulphate proteoglycans in developmental processes.** *Nature* 2000, **404**:725-728.
5. Bernfield M, Gotte M, Park PW, Reizes O, Fitzgerald ML, Lincecum J, Zako M: **Functions of cell surface heparan sulfate proteoglycans.** *Annu Rev Biochem* 1999, **68**:729-777.
6. Selleck SB: **Proteoglycans and pattern formation: sugar biochemistry meets developmental genetics.** *Trends Genet* 2000, **16**:206-212.
7. Hallgren P, Lundblad A, Svensson S: **A new type of carbohydrate-protein linkage in a glycopeptide from normal human urine.** *J Biol Chem* 1975, **250**:5312-5314.
8. Kentzer EJ, Buko AM, Menon G, Sarin VK: **Carbohydrate composition and presence of a fucose-protein linkage in recombinant human pro-urokinase.** *Biochem Biophys Res Commun* 1990, **171**:401-406.
9. Harris RJ, Spellman MW: **O-linked fucose and other post-translational modifications unique to EGF modules.** *Glycobiology* 1993, **3**:219-224.
10. Campbell ID, Bork P: **Epidermal growth factor-like modules.** *Curr Opin Struct Biol* 1993, **3**:385-392.
11. Moloney DJ, Shair L, Lu FM, Xia J, Locke R, Matta KL, Haltiwanger RS: **Mammalian Notch1 is modified with two unusual forms of O-linked glycosylation found on epidermal growth factor-like modules.** *J Biol Chem* 2000, **275**:9604-9611.
The original report of *O*-fucose modifications of Notch.
12. Schiffer SG, Foley S, Kaffashan A, Hronowski X, Zichittella A, Yeo CY, Miatkowski K, Adkins HB, Damon B, Whitman M *et al.*: **Fucosylation of Cripto is required for its ability to facilitate Nodal signaling.** *J Biol Chem* 2001, **276**:37769-37778.
The initial report describing *O*-fucose modification of human Cripto and its essential role in Nodal signaling.
13. Yan YT, Liu JJ, Luo Y, E C, Haltiwanger RS, Abate-shen C, Shen MM: **Bi-functional activity of Cripto as a ligand and co-receptor in the Nodal signaling pathway.** *Mol Cell Biol* 2002, **22**:4439-4449.
A recent report describing *O*-fucose on mouse Cripto and the importance of the *O*-fucose for Cripto–Nodal interactions.
14. Panin VM, Shao L, Lei L, Moloney DJ, Irvine KD, Haltiwanger RS: **Notch ligands are substrates for protein O-fucosyltransferase-1 and Fringe.** *J Biol Chem* 2002, **277**:29945-29952.
The authors demonstrate that Notch ligands (Delta and Serrate/Jagged) are also modified by *O*-fucose and by Fringe, and that the *O*-fucose consensus site needs to be broadened. The proposed broader consensus site is C²X₃₋₅/TC³.
15. Wang Y, Spellman MW: **Purification and characterization of a GDP-fucose: polypeptide fucosyltransferase from Chinese hamster ovary cells.** *J Biol Chem* 1998, **273**:8112-8118.
16. Wang Y, Shao L, Shi S, Harris RJ, Spellman MW, Stanley P, Haltiwanger RS: **Modification of epidermal growth factor-like repeats with O-fucose: molecular cloning of a novel GDP-fucose: protein O-fucosyltransferase.** *J Biol Chem* 2001, **276**:40338-40345.
17. Wang Y, Lee GF, Kelley RF, Spellman MW: **Identification of a GDP-L-fucose: polypeptide fucosyltransferase and enzymatic addition of O-linked fucose to EGF domains.** *Glycobiology* 1996, **6**:837-842.
18. Kao Y-H, Lee GF, Wang Y, Starovasnik MA, Kelley RF, Spellman MW, Lerner L: **The effect of O-fucosylation on the first EGF-like domain from human blood coagulation factor VII.** *Biochemistry* 1999, **38**:7097-7110.
19. Dear A, Medcalf RL: **The urokinase-type-plasminogen-activator receptor (CD87) is a pleiotropic molecule.** *Eur J Biochem* 1998, **252**:185-193.
20. Rabbani SA, Mazar AP, Bernier SM, Haq M, Bolivar I, Henkin J, Goltzman D: **Structural requirements for the growth factor activity of the amino-terminal domain of urokinase.** *J Biol Chem* 1992, **267**:14151-14156.
21. Artavanis-Tsakonas S, Rand MD, Lake RJ: **Notch signaling: cell fate control and signal integration in development.** *Science* 1999, **284**:770-776.
22. Mumm JS, Kopan R: **Notch signaling: from the outside in.** *Dev Biol* 2000, **228**:151-165.
23. Joutel A, Tournier-Lasserre E: **Notch signalling pathway and human diseases.** *Semin Cell Dev Biol* 1998, **9**:619-625.
24. Krantz ID, Smith R, Colliton RP, Tinkel H, Zackai EH, Piccoli DA, Goldmuntz E, Spinner NB: **Jagged1 mutations in patients ascertained with isolated congenital heart defects.** *Am J Med Genet* 1999, **84**:56-60.
25. Bulman MP, Kusumi K, Frayling TM, McKeown C, Garrett C, Lander ES, Krumlauf R, Hattersley AT, Ellard S, Turnpenny PD: **Mutations in the human delta homologue, DLL3, cause axial skeletal defects in spondylocostal dysostosis.** *Nat Genet* 2000, **24**:438-441.
26. Irvine KD: **Fringe, Notch, and making developmental boundaries.** *Curr Opin Genet Dev* 1999, **9**:434-441.
27. Irvine KD, Rauskolb C: **Boundaries in development: formation and function.** *Annu Rev Cell Dev Biol* 2001, **17**:189-214.
28. Cohen B, Bashirullah A, Dagnino L, Campbell C, Fisher WW, Leow CC, Whiting E, Ryan D, Zinyk D, Boulianne G *et al.*: **Fringe boundaries coincide with Notch-dependent patterning centres in**

- mammals and alter Notch-dependent development in *Drosophila*. *Nat Genet* 1997, **16**:283-288.
29. Johnston SH, Rauskolb C, Wilson R, Prabhakaran B, Irvine KD, Vogt TF: **A family of mammalian Fringe genes implicated in boundary determination and the Notch pathway.** *Development* 1997, **124**:2245-2254.
30. Moloney DJ, Panin VM, Johnston SH, Chen J, Shao L, Wilson R, Wang Y, Stanley P, Irvine KD, Haltiwanger RS *et al.*: **Fringe is a glycosyltransferase that modifies notch.** *Nature* 2000, **406**:369-375. This paper, together with [37**,38**], demonstrates that Fringe is a glycosyltransferase that modifies O-fucose residues on Notch and that the glycosyltransferase activity is essential for Fringe to be able to modulate Notch function.
31. Shimizu K, Chiba S, Saito T, Kumano K, Takahashi T, Hirai H: **Manic fringe and lunatic fringe modify different sites of the notch2 extracellular region, resulting in different signaling modulation.** *J Biol Chem* 2001, **276**:25753-25758. The authors show that Manic and Lunatic fringe can modulate Notch2-ligand binding and signaling to Notch2 in cell-based assays.
32. Hicks C, Johnston SH, DiSibio G, Collazo A, Vogt TF, Weinmaster G: **Jagged1 and Delta1 mediated Notch signaling is differentially regulated by lunatic fringe.** *Nat Cell Biol* 2000, **2**:515-520. The initial demonstration that Notch regulation by Fringe can be mimicked in a cell-based assay.
33. Evrard YA, Lun Y, Aulehla A, Gan L, Johnson RL: **Lunatic fringe is an essential mediator of somite segmentation and patterning.** *Nature* 1998, **394**:377-381.
34. Zhang N, Gridley T: **Defects in somite formation in lunatic fringe-deficient mice.** *Nature* 1998, **394**:374-377.
35. Zhang N, Norton CR, Gridley T: **Segmentation defects of Notch pathway mutants and absence of a synergistic phenotype in lunatic fringe/radical fringe double mutant mice.** *Genesis* 2002, **33**:21-28.
36. Moran JL, LeVorse JM, Vogt TF: **Limbs move beyond the radical fringe.** *Nature* 1999, **399**:742-743.
37. Bruckner K, Perez L, Clausen H, Cohen S: **Glycosyltransferase activity of Fringe modulates Notch-Delta interactions.** *Nature* 2000, **406**:411-415. Together with [30**,38**], this paper demonstrates that Fringe is a glycosyltransferase. The authors provide data suggesting that Fringe alters Notch-Delta binding interactions.
38. Munro S, Freeman M: **The notch signalling regulator fringe acts in the Golgi apparatus and requires the glycosyltransferase signature motif DXD.** *Curr Biol* 2000, **10**:813-820. Together with [30**,37**], this paper demonstrates that mutations in the putative DxD motif of Fringe prevent its ability to alter Notch signaling.
39. Chen J, Moloney DJ, Stanley P: **Fringe modulation of Jagged1 induced Notch signaling requires the action of β 4galactosyltransferase-1.** *Proc Natl Acad Sci USA* 2001, **98**:13716-13721. The addition of sialic acids is shown not to be essential for Fringe to inhibit Jagged1-induced Notch signaling. By contrast, the addition of β 1,4-galactose is required for Fringe to mediate its effects.
40. Haltiwanger RS, Stanley P: **Modulation of receptor signaling by glycosylation: Fringe is an O-fucose- β 1,3-N-acetylglucosaminyltransferase.** *Biochem Biophys Acta* 2002, in press. A more detailed review on Fringe, including several potential mechanisms for how altered carbohydrate structures on Notch result in altered Notch activity.
41. Schier AF, Shen MM: **Nodal signalling in vertebrate development.** *Nature* 2000, **403**:385-389.
42. Whitman M: **Nodal signaling in early vertebrate embryos: themes and variations.** *Dev Cell* 2001, **1**:605-617.
43. Shen MM, Schier AF: **The EGF-CFC gene family in vertebrate development.** *Trends Genet* 2000, **16**:303-309.
44. Hofsteenge J, Huwiler KG, Macek B, Hess D, Lawler J, Mosher DF, Peter-Katalinic J: **C-mannosylation and O-fucosylation of the thrombospondin type 1 module.** *J Biol Chem* 2001, **276**:6485-6498.
45. Adams JC, Tucker RP: **The thrombospondin type 1 repeat (TSR) superfamily: diverse proteins with related roles in neuronal development.** *Develop Dynamics* 2000, **218**:280-299.
46. De Celis JF, Bray SJ: **The Abruption domain of Notch regulates negative interactions between Notch, its ligands and Fringe.** *Development* 2000, **127**:1291-1302.
47. Gohlke M, Baude G, Nuck R, Grunow D, Kannicht C, Bringmann P, Donner P, Reutter W: **O-linked L-fucose is present in *Desmodus rotundus* salivary plasminogen activator.** *J Biol Chem* 1996, **271**:7381-7386.
48. Bjoern S, Foster DC, Thim L, Wiberg FC, Christensen M, Komiya Y, Pedersen AH, Kisiel W: **Human plasma and recombinant factor VII: characterization of O-glycosylation at serine residues 52 and 60 and effects of site-directed mutagenesis of serine 52 to alanine.** *J Biol Chem* 1991, **266**:11051-11057.
49. Nishimura H, Takao T, Hase S, Shimonishi Y, Iwanaga S: **Human factor IX has a tetrasaccharide O-glycosidically linked to serine 61 through the fucose residue.** *J Biol Chem* 1992, **267**:17520-17525.
50. Harris RJ, Ling VT, Spellman MW: **O-linked fucose is present in the first epidermal growth factor domain of factor XII but protein C.** *J Biol Chem* 1992, **267**:5102-5107.
51. Krogh TN, Bachmann E, Teisner B, Skjodt K, Hojrup P: **Glycosylation analysis and protein structure determination of murine fetal antigen 1 (mFA1) - The circulating gene product of the delta-like protein (dlk), preadipocyte factor 1 (Pref-1) and stromal-cell-derived protein 1 (SCP-1) cDNAs.** *Eur J Biochem* 1997, **244**:334-342.
52. Moloney DJ, Haltiwanger RS: **The O-linked fucose glycosylation pathway: identification and characterization of a UDP-glucose: O-fucose β 1,3-glucosyltransferase.** *Glycobiology* 1999, **9**:679-687.
53. Sakamoto K, Ohara O, Takagi M, Takeda S, Katsube K: **Intracellular cell-autonomous association of Notch and its ligands: a novel mechanism of Notch signal modification.** *Dev Biol* 2002, **241**:313-326.
54. Harris RJ, Leonard CK, Guzzetta AW, Spellman MW: **Tissue plasminogen activator has an O-linked fucose attached to threonine-61 in the epidermal growth factor domain.** *Biochemistry* 1991, **30**:2311-2314.
55. Schwientek T, Keck B, Lavery SB, Jensen MA, Pedersen JW, Wandall HH, Stroud M, Cohen SM, Amado M, Clausen H: **The *Drosophila* gene *Brainiac* encodes a glycosyltransferase putatively involved in glycosphingolipid synthesis.** *J Biol Chem* 2002, in press.